Access this Article

Abstract

Although dose reduction of S-1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5-fluorouracil, 5-chloro-2,4 dihydroxypyridine and oteracil potassium, and to review the recommended dose modification of S-1 in patients with renal impairment. We classified patients receiving S-1 into 4 groups according to their renal function, as measured using the Japanese estimated glomerular filtration rate (eGFR) equation. The daily S-1 dose was adjusted based on the patient's eGFR and body surface area. Blood samples were collected for pharmacokinetic analysis. A total of 33 patients were enrolled and classified into 4 groups as follows: 10 patients in cohort 1 (eGFR ≥ 80 mL/min/1.73 m(2)), 10 patients in cohort 2 (eGFR = 50-79 mL/min/1.73 m(2)), 10 patients in cohort 3 (eGFR = 30-49 mL/min/1.73 m(2)), and 3 patients in cohort 4 (eGFR < 30 mL/min/1.73 m(2)). Those in cohorts 3 and 4 treated with an adjusted dose of S-1 showed a similar area under the curve for 5-fluorouracil (941.9 ± 275.6 and 1043.5 ± 224.8 ng/mL, respectively) compared with cohort 2 (1034.9 ± 414.3 ng/mL). Notably, while there was a statistically significant difference between cohort 1 (689.6 ± 208.8 ng/mL) and 2 (P = 0.0474) treated with an equal dose of S-1, there was no significant difference observed in the toxicity profiles of the cohorts. In conclusion, dose adjustment of S-1 in patients with impaired renal function using eGFR is appropriate and safe.

Journal

  • Cancer Science

    Cancer Science 110(6), 1987-1994, 2019-06

    Wiley

Codes

  • NII Article ID (NAID)
    120006653246
  • Text Lang
    ENG
  • Article Type
    journal article
  • ISSN
    1347-9032
  • Data Source
    IR 
Page Top